Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeutics, Maintains $54 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $54 price target.
July 14, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics has received an Overweight rating and a maintained price target of $54 from Cantor Fitzgerald.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Arcturus Therapeutics. The maintained price target of $54 suggests that the analyst believes the stock is undervalued at current levels. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100